Monday, March 27, 2023 Daily Archives

eBook: The Post-Pandemic Supply Chain

by , and

Supply chains felt the full force of the COVID-19 pandemic, leading the industry to rapidly adopt new protocols. Additional forces have also exposed the supply chain to even more complex issues such as increased lead times and sustainability. This eBook examines the lessons learned from the pandemic that have become standard among biomanufacturers and how rising macroeconomic threats such as inflation and climate change continue to force supply chains to evolve. Jim Marshall, associate director of materials management at Alnylam,…

March 27, 2023

Bio-Europe Spring: Lobbyists slam US “Innovation” Reduction Act

by

President Biden’s Inflation Reduction Act (IRA) is a “penalty on success” and has already led to companies dropping clinical programs, says biopharma advocacy group BIO. At Bio Europe Spring last week, David Thomas, VP of Industry Research at lobby group the Biotechnology Innovation Organization (BIO), reflected on the “very tough times” the biotech industry has experienced over the past year due to reduced public and private funding. While he hoped macro-economic factors would resolve themselves to dig the industry out…

March 27, 2023

Recipharm’s Arranta completes RNA facility buildout

by

Recipharm says the 2,000 square-foot expansion at the Arranta Bio Watertown, Massachusetts facility will help accelerate customer RNA development projects. Less than a year after the acquisition of Boxborough, Massachusetts-based contract development and manufacturing organization (CDMO)Arranta Bio, Recipharm has expanded RNA process development capacity by 50% through a 2,000 square-foot buildout of the Watertown, facility. As well as doubling laboratory capacity, the expansion of the 80,000 square-foot commercial-ready GMP manufacturing facility includes “flexible, modular small scale and pilot scale equipment,”…

March 27, 2023

40 years of biomanufacturing history ending as Genentech shutters California plant

by

More than 260 jobs are to go as Genentech finally calls time on its legacy South San Francisco biomanufacturing facility. Constructed in 1983, the South San Francisco facility began commercial manufacturing in 1985. But as part of a long-term biomanufacturing rehaul, Roche’s Genentech will close the site in the coming months. “More than 15 years ago, we initiated a long-term strategy to evolve and modernize our manufacturing capabilities to meet the needs of patients in the future. We’re now in…

March 27, 2023

Takeda to build $770m plasma-derived therapy plant in Japan

by

The $770 million facility in Osaka, Japan will support global manufacturing and supply capabilities for plasma-derived therapies (PDTs), says Takeda. The 100-billion-yen ($770 million) venture represents Takeda’s biggest manufacturing capacity expansion investment in Japan. According to the firm, the plant will be the “largest of its kind” in the country and is anticipated to be operational by around 2030. Moreover, the facility will have almost five-times the capacity of its current PDT manufacturing site located in Narita, Japan. In turn,…

March 27, 2023